Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $21.07 USD
Change Today +0.59 / 2.88%
Volume 87.5K
ENTL On Other Exchanges
As of 8:10 PM 07/30/15 All times are local (Market data is delayed by at least 15 minutes).

entellus medical inc (ENTL) Snapshot

Previous Close
Day High
Day Low
52 Week High
04/16/15 - $28.81
52 Week Low
01/29/15 - $19.00
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for ENTELLUS MEDICAL INC (ENTL)

Related News

No related news articles were found.

entellus medical inc (ENTL) Related Businessweek News

No Related Businessweek News Found

entellus medical inc (ENTL) Details

Entellus Medical, Inc., a medical technology company, focuses on the design, development, and commercialization of products for the minimally invasive treatment of patients suffering from chronic sinusitis. The company offers XprESS Multi-Sinus Dilation family of products consisting of XprESS Pro device, XprESS LoProfile device, and XprESS Ultra device, which open an obstructed or narrowed drainage pathway of a sinus cavity by means of trans-nasal balloon sinus dilation; and FinESS sinus dilation system, a solution for treatment of the maxillary sinus drainage pathway. It also provides PathAssist tools, such as LED Light Fiber, a single-use tool that provides real-time high intensity red trans-illumination of the sinus cavity with its own battery power; Light Fiber, a single-use tool that provides real-time trans-illumination of the sinus cavity; Light Seeker, a tool with optical fibers embedded into the device to allow ear, nose, and throat (ENT) physicians to access the frontal sinus and trans-illuminate the sinus cavity, and forehead to confirm correct entry into the frontal sinus; Maxillary Seeker, a tool that allows users to find the correct angle to access the natural maxillary ostia; and Sphenoid Seeker/Freer, a two-in-one tool that enables ENT physicians to navigate access to the sphenoid ostium, and to manipulate the middle turbinate. In addition, Entellus Medical, Inc. distributes XeroGel Nasal Packing Material for use in patients undergoing nasal or sinus surgery, as well as for use as a nasal packing to treat epistaxis or nasal bleeding. The company sells its products in the United States. Entellus Medical, Inc. was founded in 2006 and is headquartered in Plymouth, Minnesota.

177 Employees
Last Reported Date: 03/19/15
Founded in 2006

entellus medical inc (ENTL) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $93.0K
Executive Chairman
Total Annual Compensation: $458.9K
Vice President of Clinical, Regulatory & Qual...
Total Annual Compensation: $240.0K
Vice President of Sales
Total Annual Compensation: $290.0K
Compensation as of Fiscal Year 2014.

entellus medical inc (ENTL) Key Developments

Entellus Medical, Inc. Appoints John K. Bakewell as a Class I Director

On July 7, 2015, the board of directors of Entellus Medical, Inc. increased the size of the Board from six to seven directors and appointed John K. Bakewell, 54, to fill the resulting vacancy. In addition, the Board appointed Mr. Bakewell to the audit committee of the Board. Mr. Bakewell will serve on the Board as a Class I director for a term expiring at the company's 2016 annual meeting of stockholders and until his successor is duly elected and qualified, or until his earlier death, resignation or removal. Mr. Bakewell has been the chief financial officer of Lantheus Holdings, Inc. since July 2014.

Entellus Medical, Inc. Presents at William Blair’s 35th Annual Growth Stock Conference, Jun-10-2015 04:40 PM

Entellus Medical, Inc. Presents at William Blair’s 35th Annual Growth Stock Conference, Jun-10-2015 04:40 PM. Venue: Four Seasons Hotel, Chicago, Illinois, United States.

Entellus Medical, Inc. Announces Unaudited Earnings Results for the First Quarter Ended March 31, 2015; Provides Earnings Guidance for the Second Quarter of 2015 and Revises Earnings Guidance for the Full Year of 2015

Entellus Medical, Inc. announced unaudited earnings results for the first quarter ended March 31, 2015. For the quarter, the company reported revenue of $13,502,000 against $10,175,000 a year ago. Loss from operations was $3,450,000 against $2,119,000 a year ago. Net loss was $4,348,000 or $0.35 per diluted share against $2,535,000 or $1.80 per diluted share a year ago. The growth in revenue was primarily attributable to an increase of approximately $3.2 million in sales of the XprESS family of products. The company estimates that second quarter 2015 revenue will range from approximately $14.8 million to $15.3 million, which would represent growth of approximately 18% to 22% versus the second quarter of 2014. The company expects that gross margin for the second quarter of 2015 will range from 77.5% to 78.5% compared to 78.3% in the second quarter of 2014. Second quarter operating expenses are expected to be in the range of $14.3 million to $15.3 million, with the increase primarily due to sales and marketing expenses related to the expansion of the U.S. sales organization, and from general and administrative expenses associated with the expense of operating as a public company. Second quarter net loss is estimated to range from approximately $2.8 million to $4.3 million, or an estimated net loss of $0.15 to $0.23 per share. The estimated net loss for the second quarter includes estimated non-cash stock-based compensation of $0.7 million to $0.8 million. The number of weighted average shares outstanding used to calculate estimated earnings per share for the second quarter is currently expected to range from approximately 18.7 million to 18.8 million. The company continues to expect full year 2015 revenue will be in a range of $58.5 million to $61.0 million, representing growth of 20% to 25% annually and that gross margin will be in a range of 77% to 78% for 2015. The company expects operating expenses to be in a range of $59 million to $62 million, including estimated charges for stock-based compensation expenses of $2.5 million to $2.7 million. This compares to the company’s previous operating expense expectation for 2015 of $60 million to $63 million. Full year 2015 net loss is now expected to be in a range of $14.0 million to $19.0 million, or a net loss of $0.80 to $1.10 per share. This compares to the company’s previous expectations for net loss in the range of $14.6 million to $20.0 million, or a net loss of $0.84 to $1.17 per share. This expected net loss per share assumes approximately 17.2 million to 17.4 million weighted average shares outstanding for the year.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ENTL:US $21.07 USD +0.59

ENTL Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Stryker Corp $101.84 USD -0.14
View Industry Companies

Industry Analysis


Industry Average

Valuation ENTL Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 4.9x
Price/Book 5.5x
Price/Cash Flow NM Not Meaningful
TEV/Sales 5.5x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ENTELLUS MEDICAL INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at